AstraZeneca Plc achieved double digit growth in both revenue and operating profit for the first quarter, driven by gains from its oncology and rare disease portfolios. During the same period, the company completed two acquisitions and announced agreements for two more. The value of the four deals is up $5.75 billion. Looking ahead to 2030, Pascal Soriot, the chief executive, said AstraZeneca aims to be a “long-term growth company.” He made his remarks on 25 April with the release of the quarterly results.
